MIDATECH PHARMA
Technologies | Sustained Release Technology




Q-Sphera® microspheres are 30µm in size and slowly dissolve, gradually releasing the drug.

Q-Sphera® Sustained Release Technology

Midatech’s sustained release technology platform (“Q-Sphera®”) enables active drug compounds to be incorporated in to sustained-release (SR) formulations with consistent precision and control. The resulting drug products ensure the drug compounds are released into the body in a highly controlled manner over a prolonged period of time from a few weeks to more than six months. The duration of release is highly tuneable and based on a well-established, FDA-approved mechanism. Briefly, Q-Sphera® encapsulates drug compounds within a biodegradable polymer matrix and forms these in to precise microparticles that can be injected under the skin or in to the muscle, where the microspheres stay and then gradually release the drug compound as they degrade. The polymer degrades in to lactic and glycolic acid, natural molecules that are safe and already present within our bodies, so are removed by natural body processes.

Q-Sphera® technology is unique in utilizing a micro-piezo technology to individually print microspheres, ensuring a narrow particle size range and predictable pharmacokinetics with low variability in blood drug concentrations.

The potential advantages of the Q-Sphera® drug delivery system over conventional dosage forms include:

Midatech’s Q-Sphera® polymer microsphere platform is being developed to enable sustained release delivery solutions for peptide and small-molecule therapeutics through precise definition of the properties of polymer microparticles into which compounds can be incorporated. Q-Sphera® microspheres are small (30µm), spherical particles that slowly dissolve, gradually releasing the drug.

Midatech's Q-Sphera® technology allows the precise formulation of drug products to achieve safe and effective delivery over a predefined period from a few weeks to more than six months. The manufacturing technology allows particles to be engineered with high precision and consistent size, alongside other key characteristics.

Markets of focus for such preparations include oncology, immunology, endocrinology, neuroscience, and ophthalmology. Midatech’s Q-Sphera® sustained release programs include:

Technologies
Sustained Release Technology




Q-Sphera® microspheres are 30µm in size and slowly dissolve, gradually releasing the drug.

Q-Sphera® Sustained Release Technology

Midatech’s sustained release technology platform (“Q-Sphera®”) enables active drug compounds to be incorporated in to sustained-release (SR) formulations with consistent precision and control. The resulting drug products ensure the drug compounds are released into the body in a highly controlled manner over a prolonged period of time from a few weeks to more than six months. The duration of release is highly tuneable and based on a well-established, FDA-approved mechanism. Briefly, Q-Sphera® encapsulates drug compounds within a biodegradable polymer matrix and forms these in to precise microparticles that can be injected under the skin or in to the muscle, where the microspheres stay and then gradually release the drug compound as they degrade. The polymer degrades in to lactic and glycolic acid, natural molecules that are safe and already present within our bodies, so are removed by natural body processes.

Q-Sphera® technology is unique in utilizing a micro-piezo technology to individually print microspheres, ensuring a narrow particle size range and predictable pharmacokinetics with low variability in blood drug concentrations.

The potential advantages of the Q-Sphera® drug delivery system over conventional dosage forms include:

Midatech’s Q-Sphera® polymer microsphere platform is being developed to enable sustained release delivery solutions for peptide and small-molecule therapeutics through precise definition of the properties of polymer microparticles into which compounds can be incorporated. Q-Sphera® microspheres are small (30µm), spherical particles that slowly dissolve, gradually releasing the drug.

Midatech's Q-Sphera® technology allows the precise formulation of drug products to achieve safe and effective delivery over a predefined period from a few weeks to more than six months. The manufacturing technology allows particles to be engineered with high precision and consistent size, alongside other key characteristics.

Markets of focus for such preparations include oncology, immunology, endocrinology, neuroscience, and ophthalmology. Midatech’s Q-Sphera® sustained release programs include:

© Copyright 2018 Midatech Pharma PLC